SCARCELL Therapeutics
Developing Cell Therapy Products for Chronic Degenerative Inflammatory Diseases
First Target: Osteoarthritis
The Problem
The Problem
The Problem
Osteoarthritis is a degenerative joint disease involving breakdown of cartilage, leading to pain, stiffness, and loss of mobility. Currently there is no cure because available treatments such as medication and injections only manage symptoms and do not address the underlying causes of the disease.
Osteoarthritis is a degenerative joint disease involving breakdown of cartilage, leading to pain, stiffness, and loss of mobility. Currently there is no cure because available treatments such as medication and injections only manage symptoms and do not address the underlying causes of the disease.
Osteoarthritis is a degenerative joint disease involving breakdown of cartilage, leading to pain, stiffness, and loss of mobility. Currently there is no cure because available treatments such as medication and injections only manage symptoms and do not address the underlying causes of the disease.
Our Solution
Our Solution
Our Solution
Scarcell is developing an allogeneic cell therapy, aeGF, with the capability to regenerate diseased cartilage.
AeGF is administered in a single intra-articular injection. Its mechanism of action is multifactorial addressing all underlying conditions by:
AeGF is administered in a single intra-articular injection. Its mechanism of action is multifactorial addressing all underlying conditions by:
AeGF is administered in a single intra-articular injection. Its mechanism of action is multifactorial addressing all underlying conditions by:
eliminating pain and inflammation
eliminating pain and inflammation
eliminating pain and inflammation
restoring cartilage.
restoring cartilage.
restoring cartilage.
AeGF has shown that it is a safe, effective and durable treatment in companion animal studies.
AeGF has shown that it is a safe, effective and durable treatment in companion animal studies.
AeGF has shown that it is a safe, effective and durable treatment in companion animal studies.
AeGF has been tested in over 800 companion animals with up to two year follow up including dogs and racehorses with naturally occurring osteoarthritis. The exceptional healing properties of aeGF are due to proven immune tolerance properties that ensure prolonged cell survival and thus long lasting therapeutic effect without the need for immune suppressant drugs.
AeGF has been tested in over 800 companion animals with up to two year follow up including dogs and racehorses with naturally occurring osteoarthritis. The exceptional healing properties of aeGF are due to proven immune tolerance properties that ensure prolonged cell survival and thus long lasting therapeutic effect without the need for immune suppressant drugs.
AeGF has been tested in over 800 companion animals with up to two year follow up including dogs and racehorses with naturally occurring osteoarthritis. The exceptional healing properties of aeGF are due to proven immune tolerance properties that ensure prolonged cell survival and thus long lasting therapeutic effect without the need for immune suppressant drugs.
AeGF and its GMP bioproduction process have been granted US Patents.
AeGF and its GMP bioproduction process have been granted US Patents.
AeGF and its GMP bioproduction process have been granted US Patents.
AeGF is entering Phase Ib clinical trials in Europe in June 2025.
AeGF is entering Phase Ib clinical trials in Europe in June 2025.
AeGF is entering Phase Ib clinical trials in Europe in June 2025.
Our Vision
Our Vision
Our Vision
Our mission is to develop safe and effective therapies that treat incurable diseases such as osteoarthritis using the power of engineered gingival fibroblasts. Treatments for additional indications such as vascular and skin diseases are under development.
Our mission is to develop safe and effective therapies that treat incurable diseases such as osteoarthritis using the power of engineered gingival fibroblasts. Treatments for additional indications such as vascular and skin diseases are under development.
Our mission is to develop safe and effective therapies that treat incurable diseases such as osteoarthritis using the power of engineered gingival fibroblasts. Treatments for additional indications such as vascular and skin diseases are under development.
